Yoshiyama Yuji, Yamaguchi Kazue, Matsuo Kazuhiro, Kurokawa Minoru, Kanke Motoko
Division of Clinical Pharmacy, Kyoritsu University of Pharmacy, 1-15-30 Shibakoen, Minato-ku, 105-8512, Tokyo, Japan.
J Infect Chemother. 2005 Feb;11(1):14-7. doi: 10.1007/s10156-004-0361-z.
The effect of coadministration of fosfomycin (FOM) on nedaplatin-induced nephrotoxicity in rats was investigated for 6 days. FOM decreased nedaplatin-induced nephrotoxicity, as shown by reduced blood urea nitrogen (BUN), serum creatinine levels, and urinary excretion of N-acetyl-beta-D-glucosaminidase (NAG). Further, there were fewer histopathological signs of nephrotoxicity in the groups treated with the combination of nedaplatin and FOM as compared with the nedaplatin-alone group. The concentration of nedaplatin was significantly lower in the renal cortex of rats treated with the combination of nedaplatin and FOM as compared with those treated with nedaplatin alone (p < 0.05). In conclusion, the concomitant administration of FOM and nedaplatin may help to achieve a chemotherapeutic strategy that reduces the nephrotoxic effects of nedaplatin.
